Enodia Therapeutics Inks Pfizer Deal to Develop Sec61-Targeting Small Molecules

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 13 Oct, 17:49 UTC

Backed by multiple Sec61 inhibitor families, proteomics and cryo-EM datasets, and machine learning-driven design, Enodia Therapeutics’ platform is the foundation of a new research collaboration and license agreement with Pfizer. The post Enodia Therapeutics Inks Pfizer Deal to Develop…